This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zackrisson, G Articles by Krantz, I Search for Related Content PubMed PubMed Citation Articles by Zackrisson, G Articles by Krantz, I

 Previous Article  |  Next Article 

J Clin Microbiol. 1990 July; 28(7): 1502-1505

Immunoglobulin A antibodies to pertussis toxin and filamentous hemagglutinin in saliva from patients with pertussis.

Department of Clinical Bacteriology, University of Göteborg, Sweden.

ABSTRACT

Immunoglobulin A (IgA) antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 181 saliva samples obtained during various stages of pertussis from 112 patients were determined. Saliva samples obtained within 5 days after the onset of symptoms did not have detectable IgA antibodies against either of the two antigens. Of the samples obtained between 6 and 50 days after the onset of symptoms, 72% had antibodies against FHA but only 40% had antibodies against PT. With few exceptions, saliva samples obtained more than 50 days after the onset of symptoms contained antibodies against both antigens. In the 59 patients from whom paired saliva samples were obtained at intervals of 2 to 5 weeks, a significant increase in the geometric mean FHA antibody titers but not PT antibody titers occurred. However, increases that were fourfold or greater were observed against FHA in only 19 patients and against PT in 14 patients. Thus, IgA antibodies against FHA and PT in saliva develop during pertussis, and the importance of secretory IgA antibodies for protection against infection and disease should be investigated. Determination of these antibodies in paired saliva samples is, however, of little value for the laboratory diagnosis of pertussis.

This article has been cited by other articles:

• Litt, D. J., Samuel, D., Duncan, J., Harnden, A., George, R. C., Harrison, T. G. (2006). Detection of anti-pertussis toxin IgG in oral fluids for use in diagnosis and surveillance of Bordetella pertussis infection in children and young adults.. J Med Microbiol 55: 1223-1228 [Abstract] [Full Text]  
• Mattoo, S., Cherry, J. D. (2005). Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies. Clin. Microbiol. Rev. 18: 326-382 [Abstract] [Full Text]  
• Hellwig, S. M. M., van Spriel, A. B., Schellekens, J. F. P., Mooi, F. R., van de Winkel, J. G. J. (2001). Immunoglobulin A-Mediated Protection against Bordetella pertussis Infection. Infect. Immun. 69: 4846-4850 [Abstract] [Full Text]  
• BERSTAD, A.K. H., HOLST, J., FROHOLM, L.O., HAUGEN, I.L., WEDEGE, E., OFTUNG, F., HANEBERG, B. (2000). A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol 49: 157-163 [Abstract] [Full Text]  
• Poulain-Godefroy, O., Mielcarek, N., Ivanoff, N., Remoue, F., Schacht, A.-M., Phillips, N., Locht, C., Capron, A., Riveau, G. (1998). Bordetella pertussis Filamentous Hemagglutinin Enhances the Immunogenicity of Liposome-Delivered Antigen Administered Intranasally. Infect. Immun. 66: 1764-1767 [Abstract] [Full Text]